These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3277907)

  • 21. [Nodal psammoma body in thyroid cancer as an indicator of cancer metastasis to the lymph node].
    Hosoya T; Sakamoto A; Kasai N; Sakurai K
    Gan No Rinsho; 1983 Sep; 29(11):1336-9. PubMed ID: 6632214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
    Hao Y; Jin C; Wang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sentinel lymph node biopsy in patients with papillary thyroid carcinoma.
    Fukui Y; Yamakawa T; Taniki T; Numoto S; Miki H; Monden Y
    Cancer; 2001 Dec; 92(11):2868-74. PubMed ID: 11753960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
    Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
    Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carcinoma of the thyroid with a mixed medullary, papillary, follicular, and undifferentiated pattern.
    Parker LN; Kollin J; Wu SY; Rypins EB; Juler GL
    Arch Intern Med; 1985 Aug; 145(8):1507-9. PubMed ID: 3896182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
    So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
    Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lateral neck lymph node metastasis in cN0 papillary thyroid carcinoma].
    Chen R; Wei T; Zhang M; Li JQ; Zou XH; Fu BH; Wang LP; Peng YL; Ma BY; Zhu JQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Aug; 47(8):662-7. PubMed ID: 23141398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sentinel lymph node biopsy in patients with papillary thyroid carcinoma].
    Nenkov R; Radev R; Madzhov R; Krasnaliev I
    Khirurgiia (Sofiia); 2006; (6):55-8. PubMed ID: 18843912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma].
    Jiang HG; Gao M; Tang WP; Li FH; Cai QZ
    Ai Zheng; 2005 Sep; 24(9):1136-9. PubMed ID: 16159441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucinous carcinoma (poorly differentiated carcinoma with extensive extracellular mucin deposition) of the thyroid: a case report with immunohistochemical studies.
    Kondo T; Kato K; Nakazawa T; Miyata K; Murata S; Katoh R
    Hum Pathol; 2005 Jun; 36(6):698-701. PubMed ID: 16021578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sonographic findings predictive of central lymph node metastasis in patients with papillary thyroid carcinoma: influence of associated chronic lymphocytic thyroiditis on the diagnostic performance of sonography.
    Yoo YH; Kim JA; Son EJ; Youk JH; Kwak JY; Kim EK; Park CS
    J Ultrasound Med; 2013 Dec; 32(12):2145-51. PubMed ID: 24277897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual findings in papillary thyroid microcarcinoma suggesting partial regression: a study of two cases.
    Simpson KW; Albores-Saavedra J
    Ann Diagn Pathol; 2007 Apr; 11(2):97-102. PubMed ID: 17349567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of presence/absence of thyroid gland on the cutoff value for thyroglobulin in lymph-node aspiration to detect metastatic papillary thyroid carcinoma.
    Zhao H; Wang Y; Wang MJ; Zhang ZH; Wang HR; Zhang B; Guo HQ
    BMC Cancer; 2017 Apr; 17(1):296. PubMed ID: 28454525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis.
    Mai KT; Vaccani JP; Thomas J; Odell PF
    Thyroid; 2001 Sep; 11(9):859-63. PubMed ID: 11575855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.
    Dencic TM; Savin SB; Selemetjev SA; Paskas SD; Zivaljevic VR; Bozic VD; Cvejic DS
    Pathol Oncol Res; 2015 Jul; 21(3):735-42. PubMed ID: 25577274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma.
    Khoo ML; Beasley NJ; Ezzat S; Freeman JL; Asa SL
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1814-8. PubMed ID: 11932323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histopathologic and immunohistochemical characterization of a primary papillary thyroid carcinoma in the lateral cervical lymph node.
    Wang Z; Qiu S; Eltorky MA; Tang WW
    Exp Mol Pathol; 2007 Feb; 82(1):91-4. PubMed ID: 17123508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytological and immunocytochemical analysis of laterocervical lymph nodes in patients with previous thyroid carcinoma.
    Pisani T; Vecchione A; Sinopoli NT; Drusco A; Valli C; Giovagnoli MR
    Anticancer Res; 1999; 19(4C):3527-30. PubMed ID: 10629647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression.
    Salajegheh A; Dolan-Evans E; Sullivan E; Irani S; Rahman MA; Vosgha H; Gopalan V; Smith RA; Lam AK
    Exp Mol Pathol; 2014 Apr; 96(2):212-8. PubMed ID: 24530443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.